血友病の世界市場の評価：タイプ別、治療別、薬剤クラス別、治療法別、流通チャネル別、地域別、機会、予測（2017年～2031年）

世界の血友病の市場規模は、2023年の131億1,000万米ドルから2031年に201億2,000万米ドルに達すると予測され、予測期間の2024年～2031年にCAGRで5.50%の成長が見込まれます。血友病の市場需要は、有病率の増加と投資家や市場参入企業の関心の高まりにより、予測期間に飛躍的に拡大する見込みです。

血友病は、体内に存在する血液凝固因子の不足により血液凝固が阻害される非常にまれな遺伝性疾患です。この疾患はX連鎖劣性遺伝性疾患であるため、男性に多く発症します。さらに、血友病の治療に使用される治療分野の発展、標的療法や併用療法へのパラダイムシフト、認知度の高まりによる診断率の向上などが追い風となり、血友病治療市場は、この疾患の疾病負担の増加とともに、予測期間により速いペースで成長すると見られます。さらに、この成長は、医薬品であれ治療法であれ、血友病の治療に使用される製品を承認することによって血友病を根絶するために政府が取った重要な取り組みによって補完されます。2024年4月、PfizerはBEQVEZ（fidanacogene elaparvovec-dzkt）について、中等度から重度の血友病Bを患う成人の治療薬として米国食品医薬品局（FDA）から承認を取得したと発表しました。これには、現在FIX予防療法を使用している者、生命を脅かす出血を起こした者、重篤な自然出血エピソードを繰り返した者、FDAが承認した検査で示されたAAVRh74varキャプシドに対する中和抗体を持たない者が含まれます。BEQVEZは1回限りの治療であり、血友病Bの患者自身がFIXを作ることができるように可能性があります。

当レポートでは、世界の血友病市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の血友病市場の見通し（2017年～2031年）

• 市場規模の分析と予測
  • 金額
• 市場シェアの分析と予測
  • タイプ別
  • 治療別
  • 薬剤クラス別
  • 治療法別
  • 流通チャネル別
  • 地域別
  • 市場シェア分析：企業別（金額）（上位5社とその他 - 2023年）
• 市場マップ分析（2023年）
  • タイプ別
  • 治療別
  • 薬剤クラス別
  • 治療法別
  • 流通チャネル別
  • 地域別

第5章 北米の血友病市場の見通し（2017年～2031年）

• 市場規模の分析と予測
  • 金額
• 市場シェアの分析と予測
  • タイプ別
  • 治療別
  • 薬剤クラス別
  • 治療法別
  • 流通チャネル別
  • シェア：国別
• 各国の市場の評価
  • 米国の血友病市場の見通し（2017年～2031年）
  • カナダ
  • メキシコ

第6章 欧州の血友病市場の見通し（2017年～2031年）

• ドイツ
• フランス
• イタリア
• 英国
• ロシア
• オランダ
• スペイン
• ポーランド

第7章 アジア太平洋の血友病市場の見通し（2017年～2031年）

• インド
• 中国
• 日本
• オーストラリア
• ベトナム
• 韓国
• インドネシア
• フィリピン

第8章 南米の血友病市場の見通し（2017年～2031年）

• ブラジル
• アルゼンチン

第9章 中東・アフリカの血友病市場の見通し（2017年～2031年）

• サウジアラビア
• アラブ首長国連邦
• 南アフリカ
• イスラエル

第10章 需給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

• 市場促進要因
• 市場の課題

第16章 市場の動向と発展

第17章 規制枠組みとイノベーション

• 臨床試験
• 規制当局の承認

第18章 特許情勢

第19章 ケーススタディ

第20章 競合情勢

• マーケットリーダー上位5社の競合マトリクス
• 上位5社のSWOT分析
• 主要企業上位10社の情勢
  • Takeda Pharmaceutical Company Limited
  • CSL Behring
  • Pfizer, Inc.
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Baxter International Inc.
  • Sanofi S.A.
  • F. Hoffmann La-Roche Ltd.
  • Novo Nordisk A/S
  • Octapharma AG

第21章 戦略的推奨

第22章 当社について、免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Global Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 3. Global Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 4. Global Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 5. Global Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 6. Global Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 7. Global Hemophilia Market Share (%), By Region, 2017-2031F
• Figure 8. North America Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 9. North America Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 10. North America Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 11. North America Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 12. North America Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 13. North America Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 14. North America Hemophilia Market Share (%), By Country, 2017-2031F
• Figure 15. United States Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 16. United States Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 17. United States Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 18. United States Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 19. United States Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 20. United States Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 21. Canada Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 22. Canada Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 23. Canada Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 24. Canada Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 25. Canada Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 26. Canada Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 27. Mexico Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 28. Mexico Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 29. Mexico Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 30. Mexico Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 31. Mexico Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 32. Mexico Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 33. Europe Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 34. Europe Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 35. Europe Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 36. Europe Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 37. Europe Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 38. Europe Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 39. Europe Hemophilia Market Share (%), By Country, 2017-2031F
• Figure 40. Germany Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 41. Germany Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 42. Germany Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 43. Germany Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 44. Germany Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 45. Germany Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 46. France Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 47. France Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 48. France Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 49. France Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 50. France Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 51. France Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 52. Italy Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 53. Italy Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 54. Italy Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 55. Italy Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 56. Italy Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 57. Italy Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 58. United Kingdom Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 59. United Kingdom Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 60. United Kingdom Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 61. United Kingdom Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 62. United Kingdom Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 63. United Kingdom Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 64. Russia Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 65. Russia Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 66. Russia Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 67. Russia Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 68. Russia Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 69. Russia Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 70. Netherlands Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 71. Netherlands Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 72. Netherlands Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 73. Netherlands Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 74. Netherlands Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 75. Netherlands Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 76. Spain Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 77. Spain Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 78. Spain Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 79. Spain Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 80. Spain Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 81. Spain Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 82. Turkey Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 83. Turkey Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 84. Turkey Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 85. Turkey Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 86. Turkey Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 87. Turkey Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 88. Poland Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 89. Poland Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 90. Poland Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 91. Poland Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 92. Poland Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 93. Poland Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 94. South America Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 95. South America Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 96. South America Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 97. South America Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 98. South America Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 99. South America Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 100. South America Hemophilia Market Share (%), By Country, 2017-2031F
• Figure 101. Brazil Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 102. Brazil Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 103. Brazil Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 104. Brazil Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 105. Brazil Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 106. Brazil Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 107. Argentina Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 108. Argentina Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 109. Argentina Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 110. Argentina Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 111. Argentina Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 112. Argentina Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 113. Asia-Pacific Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 114. Asia-Pacific Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 115. Asia-Pacific Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 116. Asia-Pacific Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 117. Asia-Pacific Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 118. Asia-Pacific Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 119. Asia-Pacific Hemophilia Market Share (%), By Country, 2017-2031F
• Figure 120. India Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 121. India Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 122. India Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 123. India Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 124. India Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 125. India Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 126. China Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 127. China Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 128. China Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 129. China Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 130. China Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 131. China Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 132. Japan Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 133. Japan Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 134. Japan Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 135. Japan Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 136. Japan Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 137. Japan Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 138. Australia Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 139. Australia Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 140. Australia Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 141. Australia Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 142. Australia Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 143. Australia Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 144. Vietnam Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 145. Vietnam Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 146. Vietnam Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 147. Vietnam Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 148. Vietnam Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 149. Vietnam Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 150. South Korea Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 151. South Korea Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 152. South Korea Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 153. South Korea Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 154. South Korea Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 155. South Korea Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 156. Indonesia Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 157. Indonesia Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 158. Indonesia Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 159. Indonesia Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 160. Indonesia Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 161. Indonesia Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 162. Philippines Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 163. Philippines Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 164. Philippines Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 165. Philippines Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 166. Philippines Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 167. Philippines Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 168. Middle East & Africa Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 169. Middle East & Africa Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 170. Middle East & Africa Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 171. Middle East & Africa Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 172. Middle East & Africa Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 173. Middle East & Africa Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 174. Middle East & Africa Hemophilia Market Share (%), By Country, 2017-2031F
• Figure 175. Saudi Arabia Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 176. Saudi Arabia Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 177. Saudi Arabia Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 178. Saudi Arabia Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 179. Saudi Arabia Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 180. Saudi Arabia Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 181. UAE Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 182. UAE Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 183. UAE Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 184. UAE Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 185. UAE Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 186. UAE Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 187. South Africa Hemophilia Market, By Value, In USD Billion, 2017-2031F
• Figure 188. South Africa Hemophilia Market Share (%), By Type, 2017-2031F
• Figure 189. South Africa Hemophilia Market Share (%), By Treatment, 2017-2031F
• Figure 190. South Africa Hemophilia Market Share (%), By Drug Class, 2017-2031F
• Figure 191. South Africa Hemophilia Market Share (%), By Therapy, 2017-2031F
• Figure 192. South Africa Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
• Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 194. By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 195. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 196. By Therapy Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 197. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global hemophilia market is projected to witness a CAGR of 5.50% during the forecast period 2024-2031, growing from USD 13.11 billion in 2023 to USD 20.12 billion in 2031. The market demand for hemophilia is anticipated to thrive drastically in the forecast years due to rising prevalence and the growing interest of investors and market players.

Hemophilia is a very rare genetic disorder where blood clotting gets impeded due to the lack of blood clotting factors present in the body. The foremost incidence of this disease takes place among males because this is an X-linked recessive disorder. Further catalyzed by developments in the therapy areas used for the treatment of hemophilia, a paradigm shift towards targeted and combination therapy, and a higher diagnosis rate on account of rising awareness, the market for hemophilia therapeutics will probably boom at a faster rate during the forecast period, with the growing disease burden of this disease. Further, this growth is complemented by significant initiatives taken by the government to eradicate hemophilia by approving the products used in treating hemophilia, whether it be pharmaceuticals or therapies. In April 2024, Pfizer Inc. stated that it received approval from the U.S. Food and Drug Administration for BEQVEZ (fidanacogene elaparvovec-dzkt) to treat adults with moderate to severe hemophilia B. It includes those who currently use FIX prophylaxis therapy, have had life-threatening hemorrhages, repeated, serious spontaneous bleeding episodes, or do not have neutralizing antibodies to AAVRh74var capsid as indicated by an FDA-approved test. BEQVEZ is a one-time treatment that might enable people with hemophilia B to make FIX themselves, as opposed to now, receiving regular intravenous infusions of FIX several times a week or month.

High Disease Burden of Hemophilia to Drive Market Growth

The global disease burden is relatively high and rising. Inheritance patterns, consanguinity, and an increasing diagnosis rate contribute to the high prevalence. Usually, a high disease burden and high demand for therapeutic products lead to higher diagnosis prevalence. As the disease burden of hemophilia increases, the demand for the hemophilia market is expected to rise. Awareness and diagnosis increase with the rise in prevalence, giving rise to the development of technologies for treatment, genetic engineering, and recombinant factor concentrates. These innovations improve patient outcomes and fuel market growth as they find widespread acceptance. Global initiatives, including the World Federation of Hemophilia and the World Health Organization (WHO), are ongoing to reduce the disease burden and create adequate awareness. For instance, if one looks at the results of the Annual Global Survey by the World Federation of Hemophilia published in October 2023, the total number of identified patients with hemophilia globally was 257,146 compared to 241,535 in 2020, thus increasing 6.46% over two years.

Advancements in Gene Therapy to Lead to Market Growth

Advancements in gene therapy are significantly driving market growth in the hemophilia market. Recent clinical trials utilizing adeno-associated viral (AAV) vectors have demonstrated stable and long-term expression of these factors, leading to significant reductions in spontaneous bleeding and the need for regular infusions. The market is further bolstered by biopharmaceutical companies' ongoing research and development efforts, which are focused on optimizing gene delivery methods and improving treatment efficacy. In June 2023, BioMarin Pharmaceutical Inc. announced that the United States Food and Drug Administration (FDA) approved ROCTAVIAN (valoctocogene roxaparvovec-rvox) gene therapy for the treatment of adults with severe hemophilia A. This type of hemophilia is characterized by congenital factor VIII (FVIII) deficiency with FVIII activity less than 1 IU/dL and without antibodies to adeno-associated virus serotype 5 (AAV5) detected by an FDA-approved test. The one-time, single-dose infusion is the first approved gene therapy for severe hemophilia A in the United States. Also, ROCTAVIAN was first approved by the European Medicines Agency in August 2022.

Hemophilia A Segment to Dominate the Hemophilia Market Share

The dominance of Hemophilia A in the hemophilia treatment market can be attributed to several key factors. Hemophilia A accounts for approximately 74.16% of all hemophilia cases globally, making it the most prevalent type of genetic disorder. This significant patient population drives the demand for targeted therapies and treatments, ensuring that Hemophilia A remains the focal point for pharmaceutical companies and healthcare providers. As per the Annual Global Survey conducted by the World Federation of Hemophilia, published in October 2023, out of 257,146 identified hemophilia patients worldwide, 208,957 were suffering from hemophilia A while 42,203 were suffering from hemophilia B and the rest were suffering from unknown type. It indicates that hemophilia A is 4.9 times more prevalent than hemophilia B. Thus, the combination of high prevalence, continuous innovation in treatment, and substantial financial implications positions Hemophilia A as the leading segment in the hemophilia market.

North America to Dominate the Hemophilia Market Share

North America leads the hemophilia market due to several interrelated factors that improve treatment accessibility and innovation. The presence of established healthcare infrastructure, specialized hemophilia treatment centers, and significant financial support for research and development further bolsters market growth. Substantial government initiatives and funding have been directed toward gene therapy and other innovative treatments, improving patient outcomes and expanding treatment options. According to the Canadian Hemophilia Society, about 3,900 Canadians are affected by hemophilia A, and about 800 Canadians suffer from hemophilia B. Similarly, the data of the National Bleeding Disorders Foundation quotes that hemophilia occurs in approximately 1 in 5,617 live male births, resulting in 30,000-33,000 males with hemophilia in the United States.

Future Market Scenario (2024 - 2031F)

Favorable reimbursement and health insurance coverage for hemophilia treatment are shaping the future market growth of the hemophilia market. The growing popularity of health insurance, especially in developing countries, enables more patients to afford expensive hemophilia treatments. Reimbursement policies are expanding to include newer therapies, such as gene therapy for hemophilia treatment. In November 2023, BioMarin Pharmaceutical Inc. reached an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) regarding the reimbursement amount for ROCTAVIAN (valoctocogene roxaparvovec-rvox) for individuals with severe hemophilia A. It marks the first gene therapy for hemophilia to establish a set federal price in Germany. ROCTAVIAN provides value to patients and the German healthcare system as a one-time, single-dose therapy administered through an intravenous infusion lasting 3-4 hours, priced at USD 31,274.25 per vial.

Key Players Landscape and Outlook

The hemophilia market is primarily dominated by players such as Novo Nordisk A/S and Baxter International Inc. Market activity reported in recent years includes business agreements, collaborations, and regulatory approvals of products. The market fosters several smaller players as well, which operate through partnerships with other players to cater to a larger market.

In June 2024, 2seventy bio, Inc. announced the completion of an asset purchase agreement by Novo Nordisk A/S. Under the terms of the agreement, Novo Nordisk acquired the Hemophilia A program and the rights to 2seventy's in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies to treat autoimmune disease. The 2seventy bio team currently involved in the program will join Novo Nordisk and continue to advance the technology.

In March 2024, ReciBioPharm AB entered into a collaboration agreement with GeneVentiv Therapeutics, Inc., a preclinical gene therapy company, to extend the development of a universal gene therapy for hemophilia based on adeno-associated virus (AAV). This therapy is reportedly the first of its kind designed to treat hemophilia patients with inhibitors. GeneVentiv's GENV-HEM (AAV8.FVa) is a single infusion, universal AAV-based gene therapy for all types of hemophilia. ReciBioPharm intends to expedite the development by leveraging its AAV manufacturing platform at its Watertown facility in Massachusetts.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Hemophilia Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Type
    • 4.2.1.1. Hemophilia A
    • 4.2.1.2. Hemophilia B
    • 4.2.1.3. Hemophilia C
  • 4.2.2. By Treatment
    • 4.2.2.1. On-demand Treatment
    • 4.2.2.2. Prophylactic Treatment
  • 4.2.3. By Drug Class
    • 4.2.3.1. Clotting Factors
      • 4.2.3.1.1. Recombinant Factor Concentrates
      • 4.2.3.1.2. Plasma-derived Factor Concentrates
    • 4.2.3.2. Monoclonal Antibodies
    • 4.2.3.3. Antidiuretic Drugs
    • 4.2.3.4. Antihemorrhagic Drugs
    • 4.2.3.5. Aminocaproic Acid
    • 4.2.3.6. Antifibrinolytic Agents
  • 4.2.4. By Therapy
    • 4.2.4.1. Replacement Therapy
    • 4.2.4.2. Immune Tolerance Induction (ITI) Therapy
    • 4.2.4.3. Gene Therapy
  • 4.2.5. By Distribution Channel
    • 4.2.5.1. Hospital Pharmacies
    • 4.2.5.2. Retail Pharmacies
    • 4.2.5.3. Specialty Centers
  • 4.2.6. By Region
    • 4.2.6.1. North America
    • 4.2.6.2. Europe
    • 4.2.6.3. Asia-Pacific
    • 4.2.6.4. South America
    • 4.2.6.5. Middle East and Africa
  • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Type
  • 4.3.2. By Treatment
  • 4.3.3. By Drug Class
  • 4.3.4. By Therapy
  • 4.3.5. By Distribution Channel
  • 4.3.6. By Region

5. North America Hemophilia Market Outlook, 2017-2031F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Type
    • 5.2.1.1. Hemophilia A
    • 5.2.1.2. Hemophilia B
    • 5.2.1.3. Hemophilia C
  • 5.2.2. By Treatment
    • 5.2.2.1. On-demand Treatment
    • 5.2.2.2. Prophylactic Treatment
  • 5.2.3. By Drug Class
    • 5.2.3.1. Clotting Factors
      • 5.2.3.1.1. Recombinant Factor Concentrates
      • 5.2.3.1.2. Plasma-derived Factor Concentrates
    • 5.2.3.2. Monoclonal Antibodies
    • 5.2.3.3. Antidiuretic Drugs
    • 5.2.3.4. Antihemorrhagic Drugs
    • 5.2.3.5. Aminocaproic Acid
    • 5.2.3.6. Antifibrinolytic Agents
  • 5.2.4. By Therapy
    • 5.2.4.1. Replacement Therapy
    • 5.2.4.2. Immune Tolerance Induction (ITI) Therapy
    • 5.2.4.3. Gene Therapy
  • 5.2.5. By Distribution Channel
    • 5.2.5.1. Hospital Pharmacies
    • 5.2.5.2. Retail Pharmacies
    • 5.2.5.3. Specialty Centers
  • 5.2.6. By Country Share
    • 5.2.6.1. United States
    • 5.2.6.2. Canada
    • 5.2.6.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Hemophilia Market Outlook, 2017-2031F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Type
        • 5.3.1.2.1.1. Hemophilia A
        • 5.3.1.2.1.2. Hemophilia B
        • 5.3.1.2.1.3. Hemophilia C
      • 5.3.1.2.2. By Treatment
        • 5.3.1.2.2.1. On-demand Treatment
        • 5.3.1.2.2.2. Prophylactic Treatment
      • 5.3.1.2.3. By Drug Class
        • 5.3.1.2.3.1. Clotting Factors
        • 5.3.1.2.3.1.1. Recombinant Factor Concentrates
        • 5.3.1.2.3.1.2. Plasma-derived Factor Concentrates
        • 5.3.1.2.3.2. Monoclonal Antibodies
        • 5.3.1.2.3.3. Antidiuretic Drugs
        • 5.3.1.2.3.4. Antihemorrhagic Drugs
        • 5.3.1.2.3.5. Aminocaproic Acid
        • 5.3.1.2.3.6. Antifibrinolytic Agents
      • 5.3.1.2.4. By Therapy
        • 5.3.1.2.4.1. Replacement Therapy
        • 5.3.1.2.4.2. Immune Tolerance Induction (ITI) Therapy
        • 5.3.1.2.4.3. Gene Therapy
      • 5.3.1.2.5. By Distribution Channel
        • 5.3.1.2.5.1. Hospital Pharmacies
        • 5.3.1.2.5.2. Retail Pharmacies
        • 5.3.1.2.5.3. Specialty Centers
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Hemophilia Market Outlook, 2017-2031F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Hemophilia Market Outlook, 2017-2031F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Hemophilia Market Outlook, 2017-2031F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Hemophilia Market Outlook, 2017-2031F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

• 17.1. Clinical Trials
• 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. Takeda Pharmaceutical Company Limited
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 20.3.2. CSL Behring
  • 20.3.3. Pfizer, Inc.
  • 20.3.4. Bayer AG
  • 20.3.5. BioMarin Pharmaceutical Inc.
  • 20.3.6. Baxter International Inc.
  • 20.3.7. Sanofi S.A.
  • 20.3.8. F. Hoffmann La-Roche Ltd.
  • 20.3.9. Novo Nordisk A/S
  • 20.3.10. Octapharma AG

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer